Clinical/Molecular RiskDirected Therapy for Newly Diagnosed Medulloblastoma

A Clinical And Molecular Risk-Directed Therapy For Newly Diagnosed Medulloblastoma

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; Parker, Melanie

    Trial Phone: 321.841.5357 ; 321-841-7561

  • IRB No: 13.198.12

    Protocol Abbrev: SJMB12

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: SJMB12

    Treatment: Radiation: Craniospinal Irradiation Other: Aerobic Training Other: Neurocognitive Remediation Drug: Chemotherapy (multiple)

    Therapies Involved: Chemotherapy ID: NCT01878617

  • Objective

    To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study

  • Key Eligibility

    Ages Eligible for Study:
    -3 Years to 21 Years
    -Genders Eligible for Study: Both
    -Accepts Healthy Volunteers: No